1-855-378-42281-855-378-4228
One of the out-patient treatment alternatives for clients in Ferguson battling with opioid abuse and addiction is called opioid maintenance therapy. Some facilities and doctors are authorized to administer specific medications to opioid addicted clients, many that are opioid-based themselves and are habit forming. With low enough amounts however, the individual does not experience high feelings but also doesn't have intense cravings and isn't in opioid withdrawal. Methadone is the first drug tried for this sole purpose, but there are alternative choices currently to choose from.
Methadone is an opioid and is meant to be taken at an out-patient clinic licensed to dispense the med, that is taken on a daily basis in liquid or pill form. The cost of the drug is around one hundred and fifty dolloars a month. Buprenorphine is also an opioid-based med, and is a pill often taken one day on, one day off. But unlike Methadone which can only be administered in well-regulated medical centers, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The cost monthly of buprenorphine is approximately $300 monthly for the generic of the drug. There is also a version of buprenorphine that contains the ingredient naloxone, which is a drug that blocks the effects of opioids. Someone taking this formulation, also known as Suboxone, would find it harder to feel high from opioids if they relapsed while taking the drug. It too is taken every day, and is priced around $450 a month. Naltrexone is another drug taken in opioid maintenance therapy, but unlike the other medications aforementioned it's an opioid blocker and isn't an opioid. A person has the choice to take this drug as a monthly shot, which is called Vivitrol. As an opioid blocker, the drug prevents someone from experience being high from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 per month.
For All Drug and Alcohol Treatment Facilities In Ferguson, Click Here.
